Over the forecast period, the Tumor Lysis Syndrome Treatment Market will register a CAGR of 6 % in terms of revenue and the global market size will reach USD 498 Million by 2029.
Tumor Lysis Syndrome Treatment Market Overview
Tumor Lysis Syndrome (TLS) is a condition in which a tumor. The market study provides a thorough explanation of the current market position, including historical and predicted market sizes based on technological growth, value, and volume, as well as cost-effective and market-leading aspects.
The market for tumor lysis syndrome therapy is being fueled by the rising frequency of hematological malignancies and greater regulatory approval for cancer treatment. In the projected term, increased research and development efforts, acquisitions, and collaboration from major key players are expected to drive the market for tumor lysis syndrome therapy. Tumor lysis syndrome occurs when tumor cells discharge their contents into the bloodstream, either as a result of treatment or on their own. Tumor lysis syndrome occurs when cancer cells break down so fast that the kidneys are unable to eliminate the material from the blood. Tumor lysis syndrome is a collection of blood-level issues that include excessive potassium (hyperkalemia), uric acid (hyperuricemia), low calcium (hypocalcemia), and phosphate (hypophosphatemia) (hyperphosphatemia).
What is our Tumor Lysis Syndrome Treatment Market report scope?
|
Report Attributes
|
Report Details
|
|
Forecast Period 2022 to 2029
|
CAGR of 0.19 % during the review period (2022 to 2029).
|
|
By Drug Type
|
- Allopurinol
- Febuxostat
- Rasburicase
- Others
|
|
By Distribution Channel
|
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
|
|
By Companies
|
- Harman Finochem Ltd
- Ironwood Pharmaceuticals, Inc.
- Mylan N.V.
- AstraZeneca
- Takeda Pharmaceutical Company Limited
- Others
|
|
Regions Covered
|
- North America
- Europe
- Asia-Pacific
- Rest of the World
|
|
Countries Covered
|
- US
- Canada
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East & Africa
- Latin America
|
|
Historical Year
|
2017 to 2021
|
|
Forecast Year
|
2022 to 2029
|
|
Number of Pages
|
119
|
|
Customization Available
|
Yes, the report can be customized as per your needs
|
Who are the Major Players in Tumor Lysis Syndrome Treatment Market?
Market Growth Reports lists all the Tumor Lysis Syndrome Treatment Market companies that are presently striving to reduce the impact of the Covid-19 pandemic on the Market- Harman Finochem Ltd, Ironwood Pharmaceuticals, Inc., Mylan N.V., AstraZeneca, Takeda Pharmaceutical Company Limited, Others
Industry News:
Takeda Obtains Additional Indication and Dosage & Administration for ADCETRIS® as a Frontline Treatment for CD30-positive Hodgkin Lymphoma in Japan
Osaka, Japan, September 21, 2018, - Takeda Pharmaceutical Company Limited, (“Takeda”) (TSE:4502) announced today that it has obtained an additional indication and dosage & administration for the use of ADCETRIS® (brentuximab vedotin; "ADCETRIS") in combination with doxorubicin, vinblastine and dacarbazine as a frontline treatment option for CD30-positive Hodgkin lymphoma patients in Japan.
What are the major Drug Type, Distribution channels for Tumor Lysis Syndrome Treatment Market?
By Drug Type, it is segmented into
- Allopurinol
- Febuxostat
- Rasburicase
- Others
By Distribution Channel it is segmented into
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Tumor Lysis Syndrome Treatment Market Regional Analysis
North America, Latin America, Europe, Asia-Pacific except Japan (APEJ), Japan, and the Middle East and Africa make up the worldwide tumor lysis syndrome therapy market (MEA). Because of increased research and development efforts and government support for the discovery of novel medications and therapies, North America is likely to be the leading regional market for tumor lysis syndrome therapy. Due to better healthcare infrastructure and an increase in the frequency of blood cancer, Europe is predicted to account for the second-largest share of the worldwide tumor lysis syndrome therapy market.
- North America
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Rest of the World
- Middle East & Africa
- Latin America
- INTRODUCTION
- MARKET DEFINITION
- MARKET DYNAMICS
- MARKET SEGMENTATION
- REPORT TIMELINES
- KEY STAKEHOLDERS
- RESEARCH METHODOLOGY
- DATA MINING
- SECONDARY RESEARCH
- PRIMARY RESEARCH
- SUBJECT MATTER EXPERT ADVICE
- QUALITY CHECK
- FINAL REVIEW
- DATA TRIANGULATION
- BOTTOM-UP APPROACH
- TOP-DOWN APPROACH
- RESEARCH FLOW
- EXECUTIVE SUMMARY
- INTRODUCTION
- GLOBAL TUMOR LYSIS SYNDROME TREATMENT MARKET BY DRUG TYPES
- GLOBAL TUMOR LYSIS SYNDROME TREATMENT MARKET BY DISTRIBUTION CHANNEL
- MARKET DYNAMICS
- DRIVERS
- INCREASING DEMAND FOR MSM SUPPLEMENT
- RESTRAINTS
- STRINGENT ENVIRONMENTAL REGULATIONS
- HIGH COST OF MATERIALS
- OPPORTUNITIES
- TUMOR LYSIS SYNDROME TREATMENT MARKET GROWTH
- APPLICATION OF TUMOR LYSIS SYNDROME TREATMENT MARKET IMPACT OF COVID 19
- GLOBAL TUMOR LYSIS SYNDROME TREATMENT MARKET, BY DRUG TYPE
- ALLOPURINOL
- FEBUXOSTAT
- RASBURICASE
- GLOBAL TUMOR LYSIS SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL
- HOSPITAL PHARMACIES
- RETAIL PHARMACIES
- ONLINE PHARMACIES
- OTHERS
- GLOBAL TUMOR LYSIS SYNDROME TREATMENT MARKET, BY REGION
- NORTH AMERICA
- EUROPE
- GERMANY
- FRANCE
- UK
- ITALY
- RUSSIA
- REST OF EUROPE
- APAC
- CHINA
- SOUTH KOREA
- JAPAN
- INDIA
- AUSTRALIA
- ASEAN
- REST OF APAC
- MIDDLE EAST & AFRICA
- SAUDI ARABIA
- UAE
- SOUTH AFRICA
- TURKEY
- REST OF MEA
- SOUTH AMERICA
- BRAZIL
- REST OF MEA
- ARGENTINA
- REST OF SOUTH AMERICA
- COMPETITIVE LANDSCAPE
- MERGERS, ACQUISITIONS, JOINT VENTURES, COLLABORATIONS,
- AND AGREEMENTS
- MARKET SHARE PERCENT/RANKING ANALYSIS
- STRATEGIES ADOPTED BY LEADING PLAYERS
- COMPANY PROFILES
- BUSINESS OVERVIEW
- COMPANY SNAPSHOT
- PRODUCT BENCHMARKING
- STRATEGIC INITIATIVES
- HARMAN FINOCHEM LTD
- IRONWOOD PHARMACEUTICALS, INC.
- MYLAN N.V.
- ASTRAZENECA
- TAKEDA PHARMACEUTICAL COMPANY LIMITED
- OTHERS
SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.
PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.
MARKET ENGINEERING
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.
EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.
REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.
